Cytokinetics, Inc.

472 articles with Cytokinetics, Inc.

• Cytokinetics to Participate in Upcoming Investor Conferences - Nov 24, 2020

  11/24/2020

  Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in virtual fireside chats at the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020, and the 3rd Annual Evercore ISI HealthCONx Conference on Thursday, December 3, 2020 at 3:05 PM ET.

• Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen

  11/23/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Amgen has elected to terminate the Collaboration and Option Agreement, dated December 20, 2006 between the companies (the “Agreement”) and thereby end its collaboration with Cytokinetics, effective May 20, 2021, and intends to transition development and commercialization rights for omecamtivmecarbil and AMG 594 to Cytokinetics.

• Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020

  11/16/2020

  Cytokinetics, Incorporated announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic cardiomyopathy were shared in three poster presentations at the American Heart Association Scientific Sessions 2020.

• Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020

  11/16/2020

  New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction

• Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medicine

  11/13/2020

  Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death Effect of Omecamtiv Mecarbil Consistent Across Most Prespecified Subgroups  with Potentially Greater Treatment Effect in Patients with Lower Ejection Fraction at Higher Risk Cytokinetics to Host Investor/Media Event and Webcast on

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 10, 2020

  11/10/2020

  Cytokinetics, Incorporated announced that on October 30, 2020 it granted stock options to purchase an aggregate of 2,850 shares of common stock to Cuong Nguyen, a new employee whose employment commenced in October 2020 as a material inducement to his employment.

• Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020

  11/6/2020

  Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET

• Cytokinetics Reports Third Quarter 2020 Financial Results

  11/4/2020

  Cytokinetics, Incorporated reported financial results for the third quarter of 2020.

• Cytokinetics to Announce Third Quarter Results on November 4, 2020

  10/21/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2020 at 4:00 PM Eastern Time.

• 

  Amgen & Cytokinetics' Cardiovascular Drug Disappoints in Phase III

  10/9/2020

  The heart drug met primary endpoint but failed to make the ultimate impact needed.

• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  10/5/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2020 it granted stock options to purchase an aggregate of 10,950 shares of common stock to three new employees whose employment commenced in September 2020 as a material inducement to their employment.

• Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

  10/5/2020

  Real-World Population Representative of P atients Enrolled in GALACTIC-HF  I ndicate a H igh- N eed, H igh- R isk P opulation with Heart Failure New Results from COSMIC-HF Show Treatment with Omecamtiv Mecarbil   Associated with Improved Right Ventricular Function SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the Heart Failure Society of America (HFSA) Virtual An

• Cytokinetics Announces Publication of Manuscript Detailing Baseline Characteristics of GALACTIC-HF in European Journal of Heart Failure

  10/2/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that a manuscript detailing the baseline characteristics from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 event driven cardiovascular out

• Cytokinetics Announces Third Annual Communications Fellowship Program Call for Proposals

  9/24/2020

  Grant s Suppor t Community Engagement for Patient Advocacy Organization s   Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 3 th , 2020 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the third annual Cytokinetics Communications Fellowship Grant program. The Communications Fellowship program provides a total of $100,000 in gran

• Cytokinetics Announces Data to Be Presented at the HFSA Virtual Annual Scientific Meeting 2020

  9/24/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data will be presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020 taking place online from September 30, 2020 – October 6, 2020. The new data include analyses characterizing real-world patients with heart failure with reduced ejection fraction (HFrEF) representative of patients in GALACTIC-HF ( G lobal A pproach to L o

• Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271Company Advances Second Cardiac Myosin Inhibitor

  9/23/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “This Phase 1 study of CK-271 builds on our longstanding approach to advance

• Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific SessionsTrial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020

  9/17/2020

  Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 pivotal cardiovascular outcomes trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), has been accepted for presentation in a virtual Late Breaking Clinical Trial session at t

• Cytokinetics to Participate in Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  Cytokinetics, Incorporated announced that the company will participate in four upcoming investor conferences.

• Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

  8/26/2020

  Cure SMA and Cytokinetics (Nasdaq:CYTK) today announced the renewal of their partnership to increase education, awareness, public policy and fundraising for spinal muscular atrophy (SMA). Cytokinetics will lend support for several of Cure SMA’s upcoming initiatives across the United States and continues as a member of the Cure SMA Industry Collaboration, a partnership between Cure SMA and pharmaceutical

• Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic CardiomyopathyCompany Makes Long-term Commitment to Outcomes Research in HCM

  8/18/2020

  Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a global registry of patients with hypertrophic cardiomyopathy (HCM) focused on improving predictive measures of risk for complications and identifying biomarkers associated with adverse clinical outcomes.